ICU Medical, Inc. (ICUI) — Financial statements
Income statement, balance sheet, and cash flow for ICU Medical, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2,230↓6.4% | 2,382↑5.4% | 2,259↓0.9% | 2,280↑73.2% | 1,316 | |
| Cost of Revenue | 1,410↓9.4% | 1,557↑2.5% | 1,519↓4.0% | 1,582↑91.8% | 825 | |
| Gross Profit | 820↓0.6% | 825↑11.5% | 740↑6.0% | 698↑42.0% | 491 | |
| Operating Expenses | ||||||
| R&D Expenses | 87↓1.3% | 89↑3.8% | 85↓8.2% | 93↑95.8% | 47 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 625↓2.1% | 639↑5.3% | 607↓0.3% | 608↑101.1% | 303 | |
| Other Expenses | 0.00↓100.0% | 54↑117.7% | 25↓36.4% | 39↑116.5% | 18 | |
| Operating Expenses | 713↓8.8% | 782↑9.0% | 717↓3.2% | 741↑101.1% | 368 | |
| Total Costs & Expenses | 2,123↓9.2% | 2,339↑4.6% | 2,236↓3.7% | 2,323↑94.7% | 1,193 | |
| Operating Results | ||||||
| Operating Income | 107↑148.9% | 43↑88.2% | 23↑153.2% | -43↓134.8% | 123 | |
| Depreciation & Amortization | 218↑8852.4% | 2↓98.9% | 229↓2.7% | 235↑136.8% | 99 | |
| EBITDA | 327↑660.0% | 43↓83.0% | 253↑32.2% | 192↓14.3% | 223 | |
| EBIT | 109↑167.8% | 41↑65.9% | 24↑156.0% | -44↓135.1% | 124 | |
| Interest & Other Income | ||||||
| Net Interest Income | -95↑0.7% | -96↓0.6% | -95↓43.5% | -66↓3448.9% | 2 | |
| Interest Income | 10↓4.5% | 11↑43.7% | 8↑69.5% | 4↑56.0% | 3 | |
| Interest Expense | 105↓1.1% | 107↑3.7% | 103↑45.1% | 71↑8152.3% | 0.86 | |
| Non-Operating Income | -2↓165.7% | 2↑251.9% | -2↓327.1% | 0.71↑176.7% | -0.92 | |
| Other Income / Expenses | -104↑4.8% | -109↓7.8% | -101↓41.4% | -72↓121105.1% | -0.06 | |
| Income Before Tax | 3↑104.8% | -66↑15.7% | -78↑31.6% | -114↓192.9% | 123 | |
| Income Tax Expense | 2↓95.3% | 52↑206.2% | -49↓21.2% | -40↓300.1% | 20 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 0.73↑100.6% | -118↓296.9% | -30↑60.1% | -74↓172.0% | 103 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 0.73↑100.6% | -118↓296.9% | -30↑60.1% | -74↓172.0% | 103 | |
| Bottom-Line Net Income | 0.73↑100.6% | -118↓296.9% | -30↑60.1% | -74↓172.0% | 103 | |
| EPS (Basic) | 0.03↑100.6% | -4.83↓292.7% | -1.23↑60.5% | -3.11↓164.0% | 4.86 | |
| EPS (Diluted) | 0.03↑100.6% | -4.83↓292.7% | -1.23↑60.5% | -3.11↓165.6% | 4.74 | |
| Weighted Average Shares | 25↑1.0% | 24↑1.2% | 24↑0.9% | 24↑12.6% | 21 | |
| Weighted Average Diluted Shares | 25↑2.1% | 24↑1.2% | 24↑0.9% | 24↑9.6% | 22 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.